Table 4 The criteria for inclusion and exclusion in the study were as follows
Inclusion criteria | Exclusion criteria |
|---|---|
Caribbean Hispanics residing in Puerto Rico Both genders (i.e., males/females) Age ≥ 21 years old Receiving clopidogrel (75 mg/day) alone or in combination with aspirin as DAPT for therapeutic indications (ACS, stable CAD, PAD). No clinically active hepatic abnormality. The ability to understand the requirements of the study. The ability to comply with the study procedures and protocols. A female patient is eligible to enter the study if she is of child-bearing potential and not pregnant or nursing, or not of child-bearing potential. | Non-Hispanic patients Currently enrolled in another active research protocols BUN > 30 and creatinine > 2.0 mg/dL Platelet count <100,000/mm3 Hematocrit (Hct) ≤ 25% Nasogastric or enteral feedings Acute illness (e.g., sepsis, infection, anemia) HIV/AIDS, Hepatitis B patients Alcoholism and drug abuse Patients with any cognitive and mental health impairment Sickle cell patients Active malignancy Patients taking another antiplatelet (i.e., other than clopidogrel and aspirin) |
